Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vascular normalization effects of faricimab in diabetic macular edema (Phase IV, Korea)
KCT0012059Phase 4Not yet recruiting
- Sponsor
- Roche
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of faricimab in diabetic macular edema (DME), sponsored by Roche. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on KCT0012059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012059.